Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences.
| Conference Details | |
| Wells Fargo 21st Annual Healthcare Conference | |
| Format: | Fireside chat and 1x1s |
| Presentation Date: | September 8, 2026 |
| Time: | 1:30 pm ET |
| Location: | Boston, MA |
| Webcast link: | HERE |
| Cantor Global Healthcare Conference, New York | |
| Format: |
1x1s |
| Participation Date: |
September 10, 2026 |
| Location: |
New York, NY |
| H.C. Wainwright 28th Annual Global Investment Conference |
|
| Format: |
Fireside chat and 1x1s |
| Presentation Date: |
September 15, 2026 |
| Time: |
10:30 am ET |
| Location: |
New York, NY |
| Webcast link: |
HERE |
To request a 1×1 meeting, please contact your representative at the relevant bank.
Webcasts of the presentations will be available for approximately 90 days following each event on the “News & Events” section of Milestone’s website www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
